Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of CD99-targeted autologous CAR-T cells in relapsed or refractory CD99-positive bone or soft tissue sarcoma
CTR20244485Phase 2Active
- Sponsor
- Wuhan Porida Biotechnology
- Start
- Dec 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CD99-targeted genetically modified autologous T-cell immunotherapy in bone cancer, soft tissue sarcoma (STS), Ewing sarcoma, rhabdomyosarcoma (RMS), osteosarcoma (OS), sponsored by Wuhan Porida Biotechnology. Started Dec 2024; status: active.
02
Drugs
CD99-targeted genetically modified autologous T-cell immunotherapy
03
Conditions
bone cancersoft tissue sarcoma (STS)Ewing sarcomarhabdomyosarcoma (RMS)osteosarcoma (OS)
Beyond the preview
Go deeper on CTR20244485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244485.